NCT Number: NCT00237965
The Use of Mole Mapping Diagrams to Increase Skin Self Examination Accuracy
This study aims to improve Skin Self-Examination accuracy by a simple cost effective intervention requiring participants to complete a mole-mapping diagram.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male and female subjects above age 18 of any ethnicity will be enrolled in this study.
Exclusion criteria
- Subjects will be excluded from the study if they have significant skin disease which would not allow manipulation of their photographs consistent with the rest of the subjects.
- Since the study instructions are in English, Non-English speakers will be excluded.
- Those with co-morbidity sufficiently severe to prevent them from being able to perform a SSE will be excluded.
- In addition, those with cognitive impairment who are unable to give informed consent, or to understand the study instructions given to them, will be excluded.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Brown University
Other
Registry information
Important dates
- First posted
- Oct 13, 2005
- Registry last updated
- Oct 13, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT05864144
Adenocarcinoma, Adnexal Diseases
Los Angeles, California, United States
View Trial DetailsSubstudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
NCT04305041
Melanoma, Neoplasms
Los Angeles, California, United States
View Trial DetailsNivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
NCT03743766
Melanoma, Neoplasms
Pittsburgh, Pennsylvania, United States
View Trial DetailsImpact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology
NCT03948724
Adenocarcinoma, Advanced Non-Small Cell Lung Cancer
Angers, France
View Trial Details